By Billy Gray
Lonza Group said its third-quarter performance was strong, with a return to growth at its capsules-and-health ingredients unit, and that it is on track to achieve full-year guidance for its core contract drug manufacturing business.
The Swiss company on Thursday reiterated full-year expectations and said both its contract development and manufacturing organization and capsules and health ingredients businesses were on track to deliver better sales results in the second half of 2025 than in the first.
The company didn't provide specific numbers for the third quarter.
Lonza said its capsules and health ingredients business returned to growth and continued its strong U.S. manufacturing presence.
The group said it expected a robust level of contract signing across technologies and sites, including at its large-scale biopharmaceuticals site in California.
It said in July that it expected its contract-drug-manufacturing sales to grow by between 20% and 21% excluding currency movements for the full year, with a core earnings before interest, taxes, depreciation and amortization margin of 30% to 31%.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
10-23-25 0151ET
